1371 articles on peptide science, safety, research, and industry news.
Latest articles: Energean shares slide 12.3% in 2026 while Brent holds above $92, Semaglutide hsCRP cut of 37.8% in SELECT suggests anti-inflammatory role, Seventh Victorian Case Links Counterfeit Retatrutide to Liver Toxicity, Seoul seizes 4,155 illegal Wegovy and Mounjaro imports in six months, Dual-targeted GRPR/FAP heterodimer improves uptake in breast tumor models, MHRA approves orforglipron, Lilly's oral GLP-1 drug, for UK use, Florida Peptide Craze Prompts Prison Sentence and FDA Compounding Move, IndexBox Lists US$4,000 UK Peptide Serum Report, No Findings, FDA Panel Backs Six Peptides for Compounding as Gray Market Draws Scrutiny, Weekly GLP-1 Drug Beats Daily Insulin in Thalassaemia-Linked Diabetes, GLP-1 Drugs May Cut Protein Intake, Raising Sarcopenia Risk, Ac 2-26 preserves retinal neurons via FPR2-p38-NOX4 suppression, Chimeric peptide H102-CP05 shows early promise for Alzheimer's therapy, Illumina Beats Earnings as Director Meister Sells $140M in Shares, FDA's Compounded GLP-1 Warning Letters and the Embody Telehealth Model, Oral Wegovy Outruns Foundayo in the First Full Quarter of Oral Competition, Circular RNA peptide drives osimertinib resistance in NSCLC via NT5C2, GLP-1 Retinopathy Meta-Analysis Finds No Class-Wide Risk Signal, GLP-1 therapy tied to rapid gains in mood and sleep in obesity, Survey: 44% of sports medicine physicians would prohibit GLP-1 drugs, QCM-D analysis maps oxyntomodulin fibril stability and release kinetics, GLP-1 therapies show cardiovascular benefit beyond glucose control, Retatrutide hits 25-30% weight loss as GLP-1 risks and benefits widen, Copper Peptides Go Mainstream in Skin Care as GHK-Cu Leads the Field, Dentist's TV Warning Adds Oral Health to GLP-1 Risk Discussion, Imperial Peptides UK sets MT-2 documentation standard for research supply, Handling Guide for Lyophilised MT-2: Identity, Storage, Traceability, AI-designed oral peptides get first commercial test in $100M deal, Meant launches LegitScript-certified GLP-1 telehealth platform, GRPR PET tracer swap at AA14 cuts pancreas uptake sharply, Tick salivary peptide cAmbly eases pain via endogenous opioids, 'Ozempic Face' Drives a 50 Percent Rise in Facial Fat Grafting, STEP 12: Semaglutide 2.4 mg Cuts Weight in Chinese Adults by 9.9 Points, Real-world tirzepatide: 68% persist, 55% adherent, 10.5% weight loss, Semaglutide Slows Rise in Dementia Risk Signature in SELECT Analysis, GLP-1 RA Plus Platinum: GI Toxicity Linked to Higher Mortality, Why Weight Returns After GLP-1 Agonist Therapy Is Stopped, Novo names AWS strategic AI partner as CagriSema decision nears, UK First in Europe to Approve Lilly's Oral GLP-1 Pill Foundayo, UK first in Europe to approve Eli Lilly oral GLP-1 orforglipron, Semaglutide Before AF Ablation Faces First Randomized Test, NCI tests neoantigen vaccine in metastatic triple-negative breast cancer, GLP-1 Analogs for Psoriatic Arthritis With Obesity and Diabetes, Federal pilot caps Medicare GLP-1 weight-loss copays at $50, Peptide Nanostructures Kill Resistant Bacteria and Restore Meropenem, ALXN2420 Phase 1: GH receptor peptide antagonist lowers IGF-1, Semaglutide Biomarker Gains Clash With Missed Alzheimer's Endpoints, Blow fly larva peptide active against MRSA with low cell toxicity, Microbiota safety should shape antimicrobial peptide development, Piramal Pharma adds spray drying suite at Turbhe peptide site, Peter Attia's Five-Question Test for Evaluating Peptides as Drugs, Yale study: hunger neurons help GLP-1 drugs sustain fat loss, MHRA Yellow Card data link GLP-1 drugs to 153 fatality reports, IndexBox Peptide Reagents Page Lists Other Markets, No Data, Tirzepatide tied to 32% lower MACE risk in real-world diabetes cohort, Gedeon Richter and Adalvo Expand Partnership to Tirzepatide Therapies, Dermatology review urges shared decision-making on GLP-1 therapies, Stage-gated workflow proposed for meat-derived bioactive peptides, GLP-1 therapies cast as pain adjuncts, not primary analgesics, Tirzepatide tied to lower predicted 10-year CVD risk over 3 years, Meta-Analyses Question Long-Term Value of GLP-1 Weight-Loss Drugs, Lilly Lifts 2026 Guidance as Tirzepatide Sales Surge, Peptide Rivals Split, Coroner ties tirzepatide to law student's fatal arrhythmia, Lilly Confirms Q1 2027 Retatrutide BLA After Phase 3 Wins, Khavinson bioregulator peptides: nuclear claims meet a clinical gap, Patent Argument Offers Rationale, Not Evidence, for Unapproved Peptides, Four peptide leads target Klebsiella DnaA in an in-silico screen, Semaglutide Slows Proteomic Dementia Risk Signature in SELECT Analysis, Semaglutide Solid Lipid Nanoparticles Boost Oral Permeability Sixfold, Standard-Lab SPPS Matches Microwave Speed, Cuts Waste, Keeps Fidelity, Peptide self-assembly death pathways classified into five themes, GLP-1 Initiation Tied to Fewer Coded GI Symptoms in IBS, GLP-1 Receptor Agonists Tied to Lower Pseudarthrosis Odds After ACDF, Eli Lilly vs Viking: Analyst Picks Lilly as the Better GLP-1 Stock, Retatrutide nears the market as physicians map GLP-1 weight-loss options, C3-targeting peptide AMY-101 shields astrocytes in NMOSD models, Imperial Peptides UK issues MOTS-C quality guide for researchers, Imperial Peptides UK Publishes Lyophilised MOTS-C Handling Guidance, Semaglutide cuts kidney events 16% in pooled 30,787-patient analysis, AI Peptide That Locks STING Dimer Speeds Diabetic Wound Healing, Durham VA joins national trial testing GLP-1 medications for alcohol use disorder, Copenhagen's New Protein Design Center Opens With 109 Million Dollar Grant, First Woman Wins Emil Fischer Medal for Synthetic Peptide Research, Cyclized Cecropin A Peptide Reaches Phase IIa for CRAB Pneumonia, FDA Panel Backs Six Unapproved Peptides for 503A Compounding List, Neoantigen peptide vaccines face a purity-testing standards gap, GLP-1 multi-target therapies and manufacturing near 2025 milestones, GenScript maps three delivery routes for neoantigen vaccines, Zero FDA Approvals: The Translational Puzzle of Cell-Penetrating Peptides, Manufacturing bottlenecks stall personalized neoantigen peptide vaccines, Huberman and Ferriss put peptide science in the mainstream, Bank of America spends $250 million a year on weight loss drugs for staff: ‘We see a great impact, Starbucks is ending GLP-1 coverage for weight loss as employer costs climb, No Link Between GLP-1 and Hypertensive Disorders of Pregnancy, Claims Data Lend Support to Tirzepatide's CV Effects in Diabetes, Shifting GLP-1 research and development: Lessons learned from the first-generation - drugdiscoverytrends.com, Craft Health’s CraftMake Platform Gets a Peptide Test Run - 3D Printing Industry, Amazon Pharmacy Launches GLP-1 Delivery for Medicare Patients, Novo Nordisk CFO Covers Oral Wegovy Rollout and Beyond, Postbiotic Supplement Boosts Body's Own GLP-1 and Weight Loss, UK Inquest Exposes Diagnostic Trap: Mounjaro Side Effects Mimic Bowel Perforation, Kalamazoo County Keeps GLP-1 Funding, Adds Co-pay for Some Staff, Amazon Pharmacy starts filling $50 Medicare GLP-1 prescriptions, Peptide Research Enters New Era as High-Purity Demand Surges, Porton Advanced Secures China Class C Drug Manufacturing License, Semaglutide: A New Treatment Option for AUD? What to Know, Novo Nordisk Names First EU Country for Wegovy Pill Launch, Vivani Medical Completes Dosing in Phase 1 Trial of Semaglutide Implant, Is Novo Nordisk Set for a 2026 Recovery Amid Competition and AI?, The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings, Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk, Retatrutide Nears Filing Amid Eli Lilly BLA Dispute, HOMETOWN HEALTH: GLP-1 drug “Tirzepatide” linked to lower heart attack risk in high-risk patients, MACE Risk May Be Reduced with GLP-1 Drug in High-Risk Patients, States and the Federal Floor for Compounded GLP-1s and Peptides, CVS Health enhances its direct-to-consumer weight management offerings, More Than 150 Deaths Reported After Weight Loss Drug Use, Everyone Wants ‘Reta.’ The Real Retatrutide Isn’t Even Available Yet., Germany first EU country to launch Wegovy oral GLP-1, Donald Bachem Obituary Notice: Wilmington, North Carolina, Everyone Wants 'Reta,' but the Real Retatrutide Isn't Available Yet, Hers Adds an AI Tool to Help Women Navigate Weight Loss and GLP-1 Use, Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs, Inside CVS Health's GLP-1 Push and Earnings Beat, Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company—finding its next blockbuster drug is proving difficult, Novo Nordisk wins Netherlands GLP-1 compounding lawsuit - pharmaphorum, How Do GLP-1s Change Brain Signaling?, On a GLP-1? Exclusive Report Says There's a Vacation for That, Lilly beats forecasts as Mounjaro, Zepbound drive 48% revenue surge, Lilly Grows Fatter On Soaring GLP-1 Revenues 08/06/2026, Could GLP-1 Drugs Lower Heart Attack Risk?, GLP-1 users double per household, Victory Medical Center Pharmacy Issues Recall of Certain Lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials Due to Elevated Endotoxin Levels, GLP-1 drug tirzepatide associated with lower risk of major cardiovascular events - News-Medical, Qnovia Secures Worldwide License For Antimicrobial Peptide Targeting Drug-Resistant Infections - Pulse 2.0, Future GLP-1 Research Hinges on Better Data Quality, Veterans Affairs Announces GLP-1 Trial for Alcohol Use Disorder, Tirzepatide Tied to Fewer Heart Events in High-Risk Diabetes Patients, GLP-1 for weight loss exceeds use for diabetes management, Eli Lilly's Weight-Loss Drug Demand Nearly Limitless: What's Next, TRIUMPH-2: Retatrutide Cuts Weight and A1C in Obesity, Eli Lilly Beats Estimates, Raises Outlook as Drug Sales Surge, Wegovy Pill Misses Expectations; Investor Concerns Debated, Fact vs. Fiction: Sorting GLP-1 Medication Myths and Science, Lilly, FDA retatrutide biologic dispute comes to a head as submission nears, Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says, GLP-1 Receptor Agonists: Mechanisms, Benefits, and Clinical Research, Lilly's Foundayo Pill Disappoints in Q2 as Injectables Boom, Novo CEO Has 'No Doubt' on Share Price Recovery as Wegovy Pill Wows, Some patients to score new super-effective 'Triple G' weight loss drug — before FDA approval - nypost.com, Understanding the Medicare GLP-1 Bridge Program - Chautauqua County, NY (.gov), Lilly climbs, Novo falls as obesity drug battle intensifies, Lilly climbs, Novo falls as obesity drug battle intensifies, Eli Lilly Widens Lead Over Novo Nordisk in GLP-1 Market, Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’, Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1, Clinicians Report Mixed Views on Retatrutide Expanded Access, What Insurance Covers Wegovy for Weight Loss, Eli Lilly Reports Higher Revenue as GLP-1 Demand Holds, Eli Lilly Raises Annual Revenue Forecast on GLP-1 Growth, Lilly earnings continue rise due to growth of Mounjaro, Zepbound sales, Pfizer Halts D&D Pharmatech Oral Obesity Drug MET-224o Trial, Wegovy Weight Loss Question Raised in 10-Word Market Report, GLP-1 Drugs Set to Reshape Bariatric Surgery, Not Replace It, Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall, Did a Weight-Loss Shot Contribute to a Grandmother's Death?, Piramal Pharma Solutions expands peptide API facility with advanced spray drying suite, Why are 90% of GLP-1 users still buying ice cream?, Zepbound Approval Question Raised in a Market Brief, GLP-1 Drugs May Have a Hidden Effect on Your Eyes, Study Finds, GLP-1 Therapy May Reduce Fracture Risk in Type 2 Diabetes, Drugmaker to Offer Early Access to Experimental GLP-1 Retatrutide, GLP-1 drugs linked to lower fracture risk in adults with type 2 diabetes | Newswise, Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat, FDA committee approves loosening peptide regulation despite own evidence - bioxconomy.com, VA Testing GLP-1 Treatment For Alcohol Use Disorder In Veterans, Three biotechs with three news updates, Trans federal employees sue over revoked health coverage, Qnovia licenses novel antimicrobial peptide, The Best Peptide Beauty Products for Firmer, Hydrated Skin, According to Dermatologists, GLP-1 Patients Advised to Look Beyond the Scale, Eli Lilly Retatrutide Early Access Opens to a Small Group of Patients Before FDA Approval, FDA peptide vote explained: Why these drugs are not approved yet, Food may taste different on GLP-1 drugs, but taste may not be the reason - News-Medical, Mounjaro Weekly Injection: Evidence Review Highlights Weight Loss, Oral Semaglutide for Weight Loss: Research and Experiences, Semaglutide or Tirzepatide for Weight Loss: The Key Question, Zepbound Pills: Is It the Right Fit for Your Weight Goals?, Scientists Computationally Design Antimicrobial Peptide Nanopores, Orforglipron: Oral GLP-1 Weight Loss Option With 72-Week Trial Data, Retatrutide Triple Agonist Update: Weight Loss and Metabolic Breakthroughs, Mounjaro vs Ozempic for Weight Loss: Market Entry 51ZCpwFmz, FDA Official Cites Concern Over Unapproved GLP-1 Weight Loss Drugs, Is Mounjaro Better Than Ozempic for Weight Loss: New Item, Mounjaro for Weight Loss: What You'll Pay in 2026, What’s behind the peptide boom and why it matters to Switzerland - SWI swissinfo.ch, Eli Lilly to allow more patients to apply for special access to unapproved obesity drug, GLP-1 use tied to obesity decline, but doctors warn of alarming misuse - NBC 5 Chicago, Cheapest Weight Loss Injection - View Q2dgy5dU8: Article, Eli Lilly Obesity Drug Access Leaves Doctors Seeking Answers.